Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin

PHASE3CompletedINTERVENTIONAL

Enrollment

214

Participants

Timeline

Start Date

October 12, 2022

Primary Completion Date

November 30, 2023

Study Completion Date

June 18, 2024

Conditions

Type 2 Diabetes

Interventions

DRUG

Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet

To be orally administered once daily for 52 weeks.

DRUG

Teneligliptin Placebo Oral Tablet

To be orally administered once daily for 52 weeks. This arm will be switched to teneligliptin from week 24.

Trial Locations (1)

Seoul National University Hospital, Seoul